Search results
Results from the WOW.Com Content Network
Clear-cell adenocarcinoma of the vagina (and/or cervix) is a rare adenocarcinoma often linked to prenatal exposure to diethylstilbestrol (DES), a drug which was prescribed in high-risk pregnancy. Presentation
Cervical cancer begins when the cells that line the cervix become abnormal and grow in a pattern that is atypical for non-cancerous cells. [14] Cervical cancer is typically first identified with an abnormal pap smear. [14] The final diagnosis of cervical cancer, including the stage of the cancer, is confirmed with additional testing. [12]
Cervical squamous intraepithelial lesion (SIL), previously called cervical intraepithelial neoplasia (CIN), is a form of dysplasia that can progress to cervical cancer. The term carcinoma in situ may be used interchangeably with high-grade SIL. [8] Ductal carcinoma in situ of the breast is the most common precancer in women. Bowen's disease is ...
Results from a phase 3 clinical trial show promise for a new standard of care for treating people with advanced cervical cancer. The new treatment includes a combination of induction chemotherapy ...
Cervical clear cell carcinoma (CCC) is typically HPV-negative, though many are p16 positive. [3] Traditionally, clear cell carcinoma of the lower genital tract in females was related to diethylstilbestrol (DES) exposure in utero. More recently, these cases develop sporadically or are related to vaginal adenosis.
The Australian Cervical Cancer Foundation (ACCF), founded in 2008, promotes 'women's health by eliminating cervical cancer and enabling treatment for women with cervical cancer and related health issues, in Australia and in developing countries.' [172] Ian Frazer, one of the developers of the Gardasil cervical cancer vaccine, is the scientific ...
Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer. [1] More specifically, CIN refers to the potentially precancerous transformation of cells of the cervix.
The Wertheim–Meigs operation is used to treat stage IA2, IB1, IB2 and IIA cervical cancers, stage II adenocarcinomas of the endometrium, upper vaginal carcinomas, uterine or cervical sarcomas, and other rare malignancies confined to the area of the cervix, uterus, and/or upper vagina. [5]